Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (57)	5/11/2004 7:52:02 PM
From: Ian@SI	Respond to of 802

Zeta, First I do appreciate the effort you made in giving such a complete response to my posts. The background is both interesting and helpful. Perhaps their non disclosure policy, for the first time, puts individuals on the same footing as institutions - both will have absolutely no facts! :-( But this is much better than an individual's relative position normally. I'll probably read the most recent 10Q/10K to see if there's anything of interest. I hadn't planned to do that 10 minutes ago. RE Halting the trial: You're presuming that enough events have occurred to trigger a DMSB evaluation. As INGN won't disclose enrolment, that's not necessarily a correct presumption. re: just explaining the reason behind what you and most people think is an insane investment.... That's usually where most money can be made. ...if you're early and right. Best regards, Ian

To: zeta1961 who wrote (57)	5/13/2004 1:48:37 PM
From: zeta1961	Respond to of 802

Preclinicals for lung cancer and INGN 241(mda7) published... Watching this molecule's progression in the clinic should be very interesting...host mechanisms...anti-metastatic of greatest interest... They also mentioned use of non-ad delivery in this paper....hmmm... Cheers!...but no champagne until the Advexin h/n trial is completed...pun intended... Zeta New Publication Highlights Anti-Metastatic Properties of Introgen's INGN 241 in Preclinical Models of Lung Cancer Thursday May 13, 1:30 pm ET AUSTIN, Texas, May 13 /PRNewswire-FirstCall/ -- Data appearing in the current issue of Molecular Therapy describe the mechanism by which expression of the mda-7 gene, the active component of INGN 241, inhibits invasion and migration of human lung cancer cells. Introgen Therapeutics, Inc. (Nasdaq: INGN - News) is developing INGN 241, currently in Phase 2 clinical trials for metastatic melanoma and has completed Phase 1 - 2 trials in multiple solid tumor indications. Researchers at Introgen and The University of Texas M. D. Anderson Cancer Center conducted the studies and the data are reported in a paper titled "Ectopic Production of MDA-7/IL-24 Inhibits Invasion and Migration of Human Lung Cancer Cells." Additional findings from these studies are scheduled to be presented at the 7th Annual Meeting of the American Society of Gene Therapy, June 2nd - 6th (Abstract #954). ADVERTISEMENT "A key challenge in treating cancer is the spread of disease from the primary tumor to disparate sites within the body," said Sunil Chada, Ph.D., Introgen's director of Research and Development. "The results of these studies demonstrate that INGN 241 inhibits the migration and invasion of lung cancer cells. Moreover, the data also define the specific proteins and molecular pathways through which this effect is mediated, which may help to expand our understanding of the molecular biology of metastasis. Our clinical and preclinical experience with INGN 241 suggests that this multi-functional product candidate may have significant utility in treating primary tumors as well as preventing the spread of cancer to other parts of the body. Reducing the number and rate of metastases may positively impact the long-term outcomes of cancer patients." In these studies, conducted in the laboratory of Dr. Rajagopal Ramesh, Assistant Professor in the Department of Thoracic and Cardiovascular Surgery at M. D. Anderson Cancer Center, the impact of INGN 241 (Ad-mda7) protein on the migration and invasion of human lung cancer cells was examined in two cultured cell lines and in animals implanted with human lung tumors. Cell culture studies demonstrated that expression of MDA-7 protein resulted in a significant decrease in cancer cell migration compared with controls. Further analysis of treated and untreated cells detected changes in several migration- related proteins, providing a molecular mechanism for the observed reduction in migration. When treated or un-treated human lung cancer cells were implanted into mice, the INGN 241-treated animals had significantly fewer lung tumor nodules, indicating a significant inhibition of metastasis. This data was validated using a non-viral method for mda-7 gene delivery in a model of human lung tumor metastasis -- again significant inhibition of metastasis was observed.